摘要
背景:20%的急性髓性白血病病人携带了一个在染色体21和染色体8之间的移位,导致了肿瘤蛋白AML1-ETO的嵌入形成。有着这样一个移位的病人虽然拥有有利的预后,但是仅仅50%能够存活5年。据预期,识别新颖的靶向治疗针对t(8;21)阳性急性髓性白血病将引导选择性治疗来提高患者的存活率。 覆盖领域:肿瘤蛋白和它需要保持自己的稳定性和功能性是第一个明显的治疗靶点。更多的是,更新的技术例如组合基因表达,DNA占有分析实验,基于高通量筛选的基因表达等引导了蛋白质或者需要肿瘤蛋白AML1-ETO导致的白血病生成通路的识别,还有调节这些蛋白质使之被认为是好的分子靶向治疗候选者。许多FDA人员赞同药物和来自传统药用植物的二次代谢物在窝藏的白血病细胞系的t(8:21)有抑制其增生的作用。 结论:为了改进t(8;21)急性髓性白血病病人的治疗方案,需要努力去解释强大的蛋白质候选者的识别使靶向治疗在最有可能的组合方式下进入临床阶段所获得的成功。
关键词: 急性髓性白血病,AML
图形摘要
Current Cancer Drug Targets
Title:Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation
Volume: 16 Issue: 3
Author(s): Rashi Arora, Sharad Sawney and Daman Saluja
Affiliation:
关键词: 急性髓性白血病,AML
摘要: Background: Twenty percent of patients with Acute Myeloid Leukemia (AML) carry a translocation between chromosomes 21 and chromosome 8 resulting in the formation of a chimeric oncoprotein AML1-ETO. The patients with this translocation although have a favourable prognosis, but the 5-year survival is only about 50%. It is anticipated that identification of novel therapeutic targets in t(8;21) positive AML will lead to treatment options that improve patient survival.
Areas covered: The oncoprotein and the proteins required to maintain its stability and functionality are the first obvious therapeutic targets. Further, newer technologies like combining gene expression and DNA occupancy profiling assays, gene expression–based high-throughput screening, etc have led to identification of proteins or pathways that are required by AML1-ETO for leukemogenesis and the agents that modulate these proteins to be considered good candidates for targeted molecular therapy. Various FDA approved drugs and secondary metabolites derived from traditional medicinal plants have been shown to possess anti-proliferative effect on t(8:21) harboring leukemic cell lines.
Conclusion: In order to improve the therapeutic regime for AML patients with t(8;21), efforts are required to translate the success achieved in identification of potent candidates for targeted therapy into clinical setup in the best possible combination.
Export Options
About this article
Cite this article as:
Rashi Arora, Sharad Sawney and Daman Saluja , Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/1568009616666151113120146
DOI https://dx.doi.org/10.2174/1568009616666151113120146 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Homodimer Model Can Resolve the Conundrum as to How Cytochrome P450 Oxidoreductase and Cytochrome b5 Compete for the Same Binding Site on Cytochrome P450c17
Current Protein & Peptide Science Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy NK Cell Function in HIV-1 Infection
Current HIV Research Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Editorial Review of 2012
Current Radiopharmaceuticals Cell Type Specific Redox Status is Responsible for Diverse Electromagnetic Field Effects
Current Medicinal Chemistry The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?
Current Cancer Drug Targets Medical Chemistry to Spy Cancer Stem Cells from Outside the Body
Mini-Reviews in Medicinal Chemistry Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity
Medicinal Chemistry Reviews - Online (Discontinued) Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency
Current Gene Therapy Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy